Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2016

Nine medicines recommended for approval, including three biosimilars

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval at its November meeting.

The CHMP recommended granting a marketing authorisation for Afstyla (lonoctocog alfa) for the prevention and treatment of bleeding in patients with haemophilia A.